Effects of a Probiotic on Body Weight
Effects of Consumption of a Probiotic Formulation on Weight Control in Obese Subjects
Probiotics administration is associated with health benefits on gut barrier integrity and immunological functions of the gastrointestinal tract. Recently, probiotics consumption was proposed to reduce fat mass and body weight in rodents (Lee HY. et al. 2006; Hamad EM. et al. 2009) as well as abdominal fat in human (Kadooka Y, 2010). The mechanisms explaining the effects of probiotics in weight control are not well understood.
The primary objective of the clinical trial is to investigate whether a consumption of a probiotic formula when compared to an intake of a placebo, is associated with a greater reduction of body weight.
Study Overview
Status
Status
Conditions
Conditions
Intervention / Treatment
Intervention / Treatment
Study Type
Study Type
Enrollment (Actual)
Enrollment
Phase
Phase
- Not Applicable
Contacts and Locations
Study Locations
-
-
Quebec
-
Québec, Quebec, Canada, G1V 0A6
- Laval University and Laval Hospital
-
-
Participation Criteria
Eligibility Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Age: between 18 and 55 years old
- Weight: 30.0 kg/m2 ≤ BMI ≤ 39.9 kg/m2
- Non smokers
- Good general health
- A 2 weeks probiotics washout period prior to treatment initiation
Exclusion Criteria:
- Under antibiotics or treatments (medication or nutritional program) affecting body weight or glucose control for the last 3 months
- Currently participating or having participated in another clinical trial during the last 6 months prior to the beginning of this study
- Pregnant women, women who have given birth in the past year, women planning pregnancy in the next 6 months or menopausal women
- Excessive consumption of products enriched in probiotics (> 4 servings per week).
- History of drug or alcohol (> 2 drinks daily) abuse
- Abnormal thyroid hormone levels
- Intake of medication that could affect body weight and/or energy expenditure
- Family history of type 2 diabetes in first degree relatives
- Allergy to the ingredients in the study product and placebo
- Participant with anaemia
- Participant with a recent history of large weight fluctuations (e.g., > 10 kg in the past year
- Immune-compromised conditions
- Participant experiencing nausea, fever, vomiting, bloody diarrhoea or severe abdominal pain
Participant with co-morbidity associated with obesity:
- Hypertension (≥ 140/90 mm Hg)
- Current use of antihypertensive medications, depression
- Prediabetes (fasting glucose >100mg/dL)
- Family history of premature coronary artery disease
- LDL > 2.0 mmol/L
- HDL < 1.3 mmol/L
- Smoking
- Obstructive sleep apnea
- Type 2 diabetes
- Cardiovascular disease.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Double
Number of Arms
Arms and Interventions
Participant Group / ArmParticipant Group / Arm |
Intervention / TreatmentIntervention / Treatment |
|---|---|
|
Experimental: Probiotic
daily probiotic consumption
|
daily probiotic consumption
|
|
Placebo Comparator: Placebo
daily placebo consumption
|
daily placebo consumption
|
What is the study measuring?
Primary Outcome Measures
Primary Outcome Measures
Outcome Measure |
Time Frame |
|---|---|
|
Body weight; Body composition (DEXA); Waist circumference
Time Frame: PRE and POST
|
PRE and POST
|
Collaborators and Investigators
Sponsor
Sponsor
Collaborators
Collaborators
Study record dates
Study Major Dates
Study Start
Study Start
Primary Completion (Actual)
Primary Completion
Study Completion (Actual)
Study Completion
Study Registration Dates
First Submitted
First Submitted
First Submitted That Met QC Criteria
First Submitted That Met QC Criteria
First Posted (Estimate)
First Posted
Study Record Updates
Last Update Posted (Estimate)
Last Update Posted
Last Update Submitted That Met QC Criteria
Last Update Submitted That Met QC Criteria
Last Verified
Last Verified
More Information
Terms related to this study
Other Study ID Numbers
Other Study ID Numbers
- 08.22 NRC
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Obesity
-
NCT06671119RecruitingObesity Prevention | Obesity Recidivism | Obesity and Overweight | Obesity and Obesity-related Medical Conditions
-
NCT05938335Not yet recruiting
-
NCT02645422Enrolling by invitation
-
NCT04780828CompletedObesity, Morbid | Obesity, Adolescent | Obesity, Abdominal | Weight, Body | Obesity, Visceral
-
NCT03843424CompletedOvernutrition | Nutrition Disorders | Overweight | Body Weight | Pediatric Obesity | Body Weight Changes | Childhood Obesity | Weight Gain | Adolescent Obesity | Obesity, Childhood
-
NCT06734312RecruitingObesity Prevention | Obesity Recidivism | Obesity and Overweight | GLP-1 | Obesity and Obesity-related Medical Conditions | Ablation Techniques
-
NCT04698135CompletedMorbid Obesity | Metabolically Healthy Obesity
-
NCT03219658Completed
-
NCT03899311Completed
-
NCT03203161Not yet recruitingMorbid Obesity | Adolescent Obesity | Bariatric Surgery
Clinical Trials on Probiotic
-
NCT07246161RecruitingFocus is on Healthy Subjects
-
NCT04980599Completed
-
NCT02920294CompletedIleostomy - Stoma
-
NCT03539913Completed
-
NCT06381193Completed
-
NCT01752803UnknownHypertension | Obesity | Type 2 Diabetes Mellitus | Hyperlipidemia
-
NCT06466174Not yet recruitingGastrointestinal Dysfunction
-
NCT03785938Unknown